ONO Pharmaceutical’s ONO-2020: A Promising Alzheimer’s Study Update

ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.

ONO Pharmaceutical Co. Ltd is conducting a Phase II clinical study titled ‘A Phase II, 26-week, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of ONO-2020 in Patients With Mild to Moderate Alzheimer’s Disease.’ The study aims to evaluate the safety and efficacy of ONO-2020, an epigenetic regulator, in improving cognitive functions in Alzheimer’s patients.

The intervention being tested is ONO-2020, administered orally in two different doses, compared to a placebo. The goal is to determine its effectiveness in enhancing memory and cognition in Alzheimer’s disease.

This interventional study is randomized with a parallel assignment model. It employs triple masking, ensuring that participants, care providers, and investigators are unaware of the treatment allocations. The primary purpose is treatment-focused.

The study began on March 2, 2025, with an estimated primary completion date yet to be announced. The latest update was submitted on June 24, 2025, indicating ongoing recruitment.

The study’s progress could influence ONO Pharmaceutical’s stock performance, as positive results may boost investor confidence and position the company favorably against competitors in the Alzheimer’s treatment market.

The study is currently ongoing, with further details available on the ClinicalTrials portal.